Efficacy and Safety of Total Oral Regimens Containing Pomalidomide as a Second-line Treatment Strategy in Multiple Myeloma Patients
10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).20241030.008
- VernacularTitle:含泊马度胺全口服方案二线治疗多发性骨髓瘤的疗效与安全性分析
- Author:
Jie XIAO
1
;
Xiuju WANG
;
Shuangfeng XIE
;
Yiqing LI
;
Guoyang ZHANG
;
Wenjuan YANG
;
Hongyun LIU
;
Danian NIE
Author Information
1. 中山大学孙逸仙纪念医院血液内科,广东广州 510120
- Keywords:
pomalidomide;
multiple myeloma;
second-line treatment;
efficacy;
safety
- From:
Journal of Sun Yat-sen University(Medical Sciences)
2024;45(6):902-911
- CountryChina
- Language:Chinese
-
Abstract:
[Objective]To evaluate the efficacy and safety of total oral regimens containing pomalidomide as a second-line treatment strategy in multiple myeloma.[Methods]A total of 22 patients with multiple myeloma placed on total oral regimens containing pomalidomide as a second-line therapy from March 2020 to December 2023 were retrospectively analyzed to evaluate the treatment response,survival and safety.[Results]The median age of the 22 patients was 71.5 years old. The total oral treatment regimens containing pomalidomide included IPD (7 cases),PCD (11 cases),XPD (2 cases),and PD (2 cases). The median number of treatment cycles was 14. Among the 13 patients with prior lenalidomide exposure,ORR was 53.85％,of which 23.08％ was ≥VGPR. In 9 patients without prior lenalidomide exposure,the ORR was 77.78％,and of which 55.56％ was ≥VGPR. There was no significant difference in ORR between these two groups (P=0.38). In 12 patients with high genetic risk,the ORR was 50％,and ≥VGPR was 16.67％. The median follow-up time was 10.6 months. Disease progressed in 10 patients and death occurred in 6 patients of them. The median progression free survival (PFS) was not reached (not reached and 10.6 months in non-lenalidomide-exposure patients or lenalidomide-exposure patients,respectively).The high grade treatment-related adverse events (AEs)(≥3 ) were reported in 18.18％ patients,including granulocytopenia,thrombocytopenia,and pulmonary infection. There was no treatment-related death.[Conclusion]Total oral regimens containing pomalidomide as a second-line therapy is generally effective and safe for multiple myeloma patients.
